Relative bioavailability and pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet oral formulation and the effect of food and gender in healthy human subjects

Back

ESC Premium Access

Relative bioavailability and pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet oral formulation and the effect of food and gender in healthy human subjects

Session: Pulmonary hypertension: progress in management, impact on outcomes

Topic: Pulmonary Hypertension

Speaker: Doctor J. Adams (San Diego, US)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor John Adams

Arena Pharmaceuticals, San Diego (United States of America)

0 follower

9 more presentations in this session

Fast screening breath analysis for diagnostics of pulmonary hypertension.

Speaker: Assistant Professor A. Swinarew (Katowice, PL)

Phenomapping to detect non-invasively patients with combined postcapillary pulmonary hypertension

Speaker: Doctor O. Raitiere (Le Havre Cedex, FR)

Impact of comorbidity on outcome in CTD-associated pulmonary arterial hypertension: data from the Swedish Pulmonary Arterial Hypertension Registry

Speaker: Doctor C. Hjalmarsson (Gothenburg, SE)

Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension

Speaker: Professor N. Galie (Bologna, IT)

Improved ten-year survival of systemic sclerosis-associated pulmonary arterial hypertension in the contemporary treatment era: a single centre retrospective study of 451 patients.

Speaker: Doctor H. Fayed (London, GB)

Access the full session

Pulmonary hypertension: progress in management, impact on outcomes

Speakers: Doctor J. Adams, Assistant Professor A. Swinarew, Doctor O. Raitiere, Doctor C. Hjalmarsson, Professor N. Galie...

Access

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources